Yale University · PharmacologyHIV Therapeutics Development Lab
Karen S. Anderson · New Haven, Connecticut
Research Focus
Dr. Karen S. Anderson's lab at Yale University focuses on developing new treatments for HIV, particularly in designing and optimizing drugs that target HIV reverse transcriptase, an essential enzyme in the HIV life cycle. The lab combines computational methods with experimental studies to develop novel anti-HIV medications that are effective against drug-resistant strains and reduce the HIV reservoirs in patients. By creating long-acting and combination therapies, they aim to improve patient compliance and overall treatment outcomes for those living with HIV.
HIVreverse transcriptaseantiretroviral therapydrug resistancecombination therapylong-acting therapiespre-exposure prophylaxis (PrEP)Gag-Pol dimerizationHIV protease
Research Aims
5AIM 01Develop new NNRTIs with improved safety and efficacy against HIV.
AIM 02Optimize lead compounds for better interaction with drug-resistant strains.
AIM 03Create novel therapeutic strategies to tackle HIV reservoirs.
AIM 04Investigate the role of Gag-Pol dimerization in HIV treatment.
AIM 05Design combination therapy approaches to enhance patient compliance.
Skills the Lab Values
PCRcell culturemouse modelsflow cytometryWestern blotRNA sequencingcomputer-aided drug designin vitro assayspharmacokinetics
Output against the department
Publications435top 13% of dept.61st of 462
this lab
most publishedleast published
Citations14ktop 28% of dept.130th of 462
this lab
most citedleast cited
Career totals from OpenAlex, compared against labs that share a department. A department spans everything from one paper to tens of thousands, so bar heights are on a log scale — otherwise the largest lab would flatten every other bar to a line.